Denmark on Thursday approved an antiviral COVID-19 drug produced by Merck and Ridgeback Biotherapeutics for at-risk patients with symptoms, including the elderly. The Scandinavian country became ...

Outside advisers to the U.S. Food and Drug Administration (FDA) on Tuesday narrowly voted to recommend the agency grant emergency use authorization (EUA) for a drug ...

A new analysis of clinical trial results shows that Merck’s antiviral pill for treating COVID-19 is significantly less effective than previously reported in October, the company ...

Britain’s medicines regulator has given a green light on Thursday to an antiviral COVID-19 pill jointly developed by U.S.-based Merck and partner Ridgeback Biotherapeutics. The drug, known ...

Merck has reached an agreement that will let other drug makers produce its COVID-19 pill, though many countries are excluded from the pact.

AMSTERDAM—The pharmaceutical company Merck says it has asked the European Medicines Agency to authorize its COVID-19 antiviral treatment, the first pill that has been shown to ...

The Bill & Melinda Gates Foundation will fund up to $120 million worth of an experimental drug that is used in treating COVID-19 to assist lower-income countries ...

A new COVID-19 pill that can purportedly cut the risk of both hospitalization as well as death from COVID-19—by as much as 50 percent—is now in ...

Merck is set to get $712 per treatment course for its COVID-19 pill from the U.S. government—even as it costs a fraction of that to produce, ...

Merck and its partner on Monday announced they filed an emergency use authorization application with the U.S. Food and Drug Administration (FDA) for their oral antiviral ...

Results from a clinical trial show that Merck’s antiviral pill for COVID-19 is effective, the company said Friday. The antiviral, molnupiravir, cut the risk of hospitalization ...

Pharmaceutical company Merck is requesting emergency use authorization for an experimental COVID-19 drug. It targets the CCP (Chinese Communist Party) virus’s ability to make copies of itself.

Inflation, a key indicator closely watched by the Fed, is still at historically high levels. Is it going to slow down growth going forward? Drugmaker Merck’s ...

Ken Frazier, the longtime chief executive of Merck and one of the few remaining Black CEOs of a Fortune 500 company, is retiring.

The U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD), will purchase an additional 100 million doses of COVID-19 investigational vaccine from ...